Synaptogenix, Inc. financial data

Symbol
SNPX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1185 Avenue Of The Americas, 3 Rd Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
NEUROTROPE BIOSCIENCE, INC. (to 11/20/2020)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 540 % -72.5%
Debt-to-equity 40.2 % +191%
Return On Equity -42.1 % -2077%
Return On Assets -29.4 % -1750%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.36M shares -93.4%
Common Stock, Shares, Outstanding 1.36M shares -92.3%
Entity Public Float 6.62M USD -81.2%
Common Stock, Value, Issued 137 USD -92.2%
Weighted Average Number of Shares Outstanding, Basic 1.32M shares +208%
Weighted Average Number of Shares Outstanding, Diluted 1.32M shares +208%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.75M USD -37.6%
General and Administrative Expense 5.01M USD -45.9%
Nonoperating Income (Expense) -1.45M USD -113%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -8.22M USD -1367%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -8.22M USD -1367%
Earnings Per Share, Basic -24.8 USD/shares -193%
Earnings Per Share, Diluted 4.58 USD/shares +445%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.6M USD -38.1%
Assets, Current 22.3M USD -31.1%
Property, Plant and Equipment, Net 14.1K USD -28.5%
Assets 22.8M USD -29.5%
Accounts Payable, Current 286K USD +33.7%
Accrued Liabilities, Current 54.5K USD -28.7%
Liabilities, Current 341K USD -81.2%
Liabilities 9.71M USD +147%
Accumulated Other Comprehensive Income (Loss), Net of Tax 5.7K USD
Retained Earnings (Accumulated Deficit) -41.5M USD -28.2%
Stockholders' Equity Attributable to Parent 12.8M USD -52.1%
Liabilities and Equity 22.8M USD -29.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.83M USD -8%
Net Cash Provided by (Used in) Financing Activities 553K USD -95.6%
Net Cash Provided by (Used in) Investing Activities -500K USD -24434%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 1.36M shares -92.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.6M USD -38.1%
Deferred Tax Assets, Valuation Allowance 30.2M USD +14.8%
Payments to Acquire Property, Plant, and Equipment 2.04K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.13M USD -1572%
Deferred Tax Assets, Operating Loss Carryforwards 31.5M USD +14.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Additional Paid in Capital 54.3M USD -8.14%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.4K USD -17.2%
Share-based Payment Arrangement, Expense 36.7K USD -98.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%